论文部分内容阅读
非小细胞肺癌(NSCLC)在所有肺癌中所占比例比较高,达75%～80%,但所有治疗措施中仅10%有一定效果,其它均不能令人满意.随着科学的发展,人们从分子水平上对其发病机理的了解也越来越深刻,并逐渐认识到,这类癌症的发生与多基因的变异有关,其中,p53抑癌基因的突变(如Tp53)在人类肺癌中最为普遍,因此,肺癌细胞中野生型p53功能的恢复有可能抑制肿瘤细胞的生长.本研究观察了表达野生型p53的逆转录病毒载体应用于原位肺癌的治疗效果.
The proportion of non-small cell lung cancer (NSCLC) in all lung cancers is relatively high, ranging from 75% to 80%, but only 10% of all treatment measures have a certain effect, others are unsatisfactory. With the development of science, people At the molecular level, the understanding of its pathogenesis has become more and more profound, and it has been gradually recognized that the occurrence of this kind of cancer is related to the mutation of multiple genes. Among them, mutations in the p53 tumor suppressor gene (such as Tp53) are most common in human lung cancer. In general, the recovery of wild-type p53 function in lung cancer cells may inhibit the growth of tumor cells. This study was to observe the effect of retroviral vector expressing wild-type p53 in the treatment of lung cancer in situ.